Skip to main content

Ben Burnett

Stock Analyst at Wells Fargo

Total Price Targets
8
Stocks Covered
6
Sectors
Healthcare
Most Recent
Dec 30, 2025

Notable Calls (Last 12 Months)

Most Bullish

  • RARE+128.2%
    Ultragenyx Pharmaceutical Inc.
    $45.00 targetDec 30, 2025

Most Bearish

  • RARE+128.2%
    Ultragenyx Pharmaceutical Inc.
    $45.00 targetDec 30, 2025

Stocks Covered by Ben Burnett

SymbolCompanyLatest TargetCurrent PriceUpside# TargetsLast Updated
RAREUltragenyx Pharmaceutical Inc.$45.00$24.79+81.6%1Dec 30, 2025
ACLXArcellx, Inc.$122.00$115.07+6.0%1Oct 18, 2024
IDYAIDEAYA Biosciences, Inc.$66.00$28.27+133.5%3Sep 23, 2024
RVMDRevolution Medicines, Inc.$43.00$140.52-69.4%1Apr 19, 2024
IRONDisc Medicine, Inc.$71.00$67.31+5.5%1Apr 1, 2024
CABACabaletta Bio, Inc.$32.00$2.94+986.6%1Mar 21, 2024

Recent Activity

  • Dec 30, 2025— Set$45.00price target onRARE(Ultragenyx Pharmaceutical Inc.)
  • Oct 18, 2024— Set$122.00price target onACLX(Arcellx, Inc.)
  • Sep 23, 2024— Set$66.00price target onIDYA(IDEAYA Biosciences, Inc.)
  • Sep 10, 2024— Set$68.00price target onIDYA(IDEAYA Biosciences, Inc.)
  • Jun 3, 2024— Set$63.00price target onIDYA(IDEAYA Biosciences, Inc.)
  • Apr 19, 2024— Set$43.00price target onRVMD(Revolution Medicines, Inc.)
  • Apr 1, 2024— Set$71.00price target onIRON(Disc Medicine, Inc.)
  • Mar 21, 2024— Set$32.00price target onCABA(Cabaletta Bio, Inc.)

Frequently Asked Questions

Who is Ben Burnett?

Ben Burnett is a stock analyst at Wells Fargo covering 6 stocks primarily in Healthcare. They have issued 8 price targets since Mar 21, 2024.

What stocks does Ben Burnett cover?

Ben Burnett currently covers 6 stocks, including IDYA, RARE, ACLX, RVMD, IRON.

What is Ben Burnett's latest price target?

Ben Burnett's most recent price target was $45.00 on RARE (Ultragenyx Pharmaceutical Inc.), set on Dec 30, 2025.

What is Ben Burnett's highest price target?

Ben Burnett's highest issued price target is $122.00 on ACLX, set on Oct 18, 2024.

Coverage based on publicly published price targets. Not investment advice.